Tomasevic ZI - Search Results

1

Incidence of brain metastases in early stage HER2 3+ breast cancer patients; is there a role for brain CT in asymptomatic patients?

Tomasevic ZI, Rakocevic Z, Tomasevic ZM, Milovanovic Z, Inic M, Kolarevic D, Lukic V, Kovac Z. Tomasevic ZI, et al. J BUON. 2012 Apr-Jun;17(2):249-53. J BUON. 2012. PMID: 22740201

2

Brain metastases as late breast cancer relapse. Single institution experience and review of the literature.

Tomasevic Z, Radosevic-Jelic Lj, Jovanovic D, Milovanovic Z, Tomasevic ZM, Jelic S, Borojevic N. Tomasevic Z, et al. J BUON. 2009 Apr-Jun;14(2):225-8. J BUON. 2009. PMID: 19650170 Clinical Trial.

3

Do we know how many cancer patients have a family history of cancer?

Andjelic-Dekic N, Tomasevic Z, Milosevic S, Kolarevic D, Jelic S. Andjelic-Dekic N, et al. J BUON. 2010 Jan-Mar;15(1):127-30. J BUON. 2010. PMID: 20414939

4

Clinical and pathological response to induction chemotherapy used as a prognostic factor in inflammatory breast cancer. Single institution experience.

Kolarevic D, Tomasevic Z, Dzodic R, Gavrilovic D, Zegarac M. Kolarevic D, et al. J BUON. 2012 Jan-Mar;17(1):21-6. J BUON. 2012. PMID: 22517688

5

Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - results from a prospective, single center, case control study.

Kovac M, Kovac Z, Tomasevic Z, Vucicevic S, Djordjevic V, Pruner I, Radojkovic D. Kovac M, et al. Eur J Intern Med. 2015 Jan;26(1):63-7. doi: 10.1016/j.ejim.2014.12.015. Epub 2015 Jan 12. Eur J Intern Med. 2015. PMID: 25592075

6

Breast cancer and recurrent thrombosis - Results from prospective single center study.

Kovac M, Kovac Z, Tomasevic Z, Tomic B, Gvozdenov M, Radojkovic D. Kovac M, et al. Breast J. 2019 Jul;25(4):783-785. doi: 10.1111/tbj.13326. Epub 2019 May 12. Breast J. 2019. PMID: 31079419 No abstract available.

7

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Martin M, et al. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. Lancet Oncol. 2017. PMID: 29146401 Clinical Trial.

8

Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.

von Minckwitz G, Colleoni M, Kolberg HC, Morales S, Santi P, Tomasevic Z, Zhang N, Hanes V. von Minckwitz G, et al. Lancet Oncol. 2018 Jul;19(7):987-998. doi: 10.1016/S1470-2045(18)30241-9. Epub 2018 Jun 4. Lancet Oncol. 2018. PMID: 29880292 Clinical Trial.

9

Oral administration of antineoplastic agents: the challenges for healthcare professionals.

Tadic D, Spasojevic IB, Tomasevic ZI, Dejanovic SD. Tadic D, et al. Among authors: tomasevic zi. J BUON. 2015 May-Jun;20(3):690-8. J BUON. 2015. PMID: 26214619 Free article. Review.

10

The changes of serum immunoglobulins in patients treated by a combination of anti-CD20 monoclonal antibody rituximab plus chlorambucil for low-grade non- Hodgkin's lymphoma.

Marinković M, Milosević D, Tomasević Z, Jelić S. Marinković M, et al. J BUON. 2002 Oct-Dec;7(4):331-5. J BUON. 2002. PMID: 17955576

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Search Page

Filters